Balaji Prasad
Stock Analyst at Barclays
(3.37)
# 1,010
Out of 5,043 analysts
132
Total ratings
47.58%
Success rate
3.58%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $7.22 | +246.26% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $10.25 | +7.32% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $21.33 | +12.52% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $10.42 | -13.63% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $139.33 | +43.54% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $22.27 | -14.68% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $68.17 | -11.98% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $147.53 | +65.39% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $7.06 | +239.94% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $41.70 | -47.24% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $647.40 | -19.68% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $19.61 | +32.59% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.47 | +17.48% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $8.13 | +121.40% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.61 | +177.01% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.60 | +337.50% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $7.22
Upside: +246.26%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $10.25
Upside: +7.32%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $21.33
Upside: +12.52%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $10.42
Upside: -13.63%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $139.33
Upside: +43.54%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $22.27
Upside: -14.68%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $68.17
Upside: -11.98%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $147.53
Upside: +65.39%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $7.06
Upside: +239.94%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $41.70
Upside: -47.24%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $647.40
Upside: -19.68%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $19.61
Upside: +32.59%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.47
Upside: +17.48%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $8.13
Upside: +121.40%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.61
Upside: +177.01%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.60
Upside: +337.50%